Enhancing the dissolution of phenylbutazone using Syloid® based mesoporous silicas for oral equine applications

Laura J. Waters, John P. Hanrahan, Joseph M. Tobin, Catherine V. Finch, Gareth M.B. Parkes, Shamsuddeen A. Ahmad, Faraj Mohammad, Maria Saleem

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Three mesoporous silica excipients (Syloid® silicas AL-1 FP, XDP 3050 and XDP 3150) were formulated with a model drug known for its poor aqueous solubility, namely phenylbutazone, in an attempt to enhance the extent and rate of drug dissolution. Although other forms of mesoporous silica have been investigated in previous studies, the effect of inclusion with these specific Syloid® silica based excipients and more interestingly, with phenylbutazone, is unknown. This work reports a significant enhancement for both the extent and rate of drug release for all three forms of Syloid® silica at a 1:1 drug:silica ratio over a period of 30 min. An explanation for this increase was determined to be conversion to the amorphous form and an enhanced drug loading ability within the pores. Differences between the release profiles of the three silicas were concluded to be a consequence of the physicochemical differences between the three forms. Overall, this study confirms that Syloid® silica based excipients can be used to enhance dissolution, and potentially therefore bioavailability, for compounds with poor aqueous solubility such as phenylbutazone. In addition, it has been confirmed that drug release can be carefully tailored based on the choice of Syloid® silica and desired release profile.

LanguageEnglish
Pages181-186
Number of pages6
JournalJournal of Pharmaceutical Analysis
Volume8
Issue number3
Early online date31 Jan 2018
DOIs
Publication statusPublished - Jun 2018

Fingerprint

Phenylbutazone
Silicon Dioxide
Horses
Dissolution
Silica
Excipients
Pharmaceutical Preparations
Solubility
Ephrin-A5
Biological Availability

Cite this

Waters, Laura J. ; Hanrahan, John P. ; Tobin, Joseph M. ; Finch, Catherine V. ; Parkes, Gareth M.B. ; Ahmad, Shamsuddeen A. ; Mohammad, Faraj ; Saleem, Maria. / Enhancing the dissolution of phenylbutazone using Syloid® based mesoporous silicas for oral equine applications. In: Journal of Pharmaceutical Analysis. 2018 ; Vol. 8, No. 3. pp. 181-186.
@article{a75cea9f51ad4b508c8cbb1777b19fac,
title = "Enhancing the dissolution of phenylbutazone using Syloid{\circledR} based mesoporous silicas for oral equine applications",
abstract = "Three mesoporous silica excipients (Syloid{\circledR} silicas AL-1 FP, XDP 3050 and XDP 3150) were formulated with a model drug known for its poor aqueous solubility, namely phenylbutazone, in an attempt to enhance the extent and rate of drug dissolution. Although other forms of mesoporous silica have been investigated in previous studies, the effect of inclusion with these specific Syloid{\circledR} silica based excipients and more interestingly, with phenylbutazone, is unknown. This work reports a significant enhancement for both the extent and rate of drug release for all three forms of Syloid{\circledR} silica at a 1:1 drug:silica ratio over a period of 30 min. An explanation for this increase was determined to be conversion to the amorphous form and an enhanced drug loading ability within the pores. Differences between the release profiles of the three silicas were concluded to be a consequence of the physicochemical differences between the three forms. Overall, this study confirms that Syloid{\circledR} silica based excipients can be used to enhance dissolution, and potentially therefore bioavailability, for compounds with poor aqueous solubility such as phenylbutazone. In addition, it has been confirmed that drug release can be carefully tailored based on the choice of Syloid{\circledR} silica and desired release profile.",
keywords = "dissolution, drug-loading, phenylbutazone, solubility, Syloid{\circledR}, Syloid{\circledR} silicas, Solubility, Phenylbutazone, Drug-loading, Dissolution",
author = "Waters, {Laura J.} and Hanrahan, {John P.} and Tobin, {Joseph M.} and Finch, {Catherine V.} and Parkes, {Gareth M.B.} and Ahmad, {Shamsuddeen A.} and Faraj Mohammad and Maria Saleem",
year = "2018",
month = "6",
doi = "10.1016/j.jpha.2018.01.004",
language = "English",
volume = "8",
pages = "181--186",
journal = "Journal of Pharmaceutical Analysis",
issn = "2095-1779",
publisher = "Xi'an Jiaotong University",
number = "3",

}

Enhancing the dissolution of phenylbutazone using Syloid® based mesoporous silicas for oral equine applications. / Waters, Laura J.; Hanrahan, John P.; Tobin, Joseph M.; Finch, Catherine V.; Parkes, Gareth M.B.; Ahmad, Shamsuddeen A.; Mohammad, Faraj; Saleem, Maria.

In: Journal of Pharmaceutical Analysis, Vol. 8, No. 3, 06.2018, p. 181-186.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enhancing the dissolution of phenylbutazone using Syloid® based mesoporous silicas for oral equine applications

AU - Waters, Laura J.

AU - Hanrahan, John P.

AU - Tobin, Joseph M.

AU - Finch, Catherine V.

AU - Parkes, Gareth M.B.

AU - Ahmad, Shamsuddeen A.

AU - Mohammad, Faraj

AU - Saleem, Maria

PY - 2018/6

Y1 - 2018/6

N2 - Three mesoporous silica excipients (Syloid® silicas AL-1 FP, XDP 3050 and XDP 3150) were formulated with a model drug known for its poor aqueous solubility, namely phenylbutazone, in an attempt to enhance the extent and rate of drug dissolution. Although other forms of mesoporous silica have been investigated in previous studies, the effect of inclusion with these specific Syloid® silica based excipients and more interestingly, with phenylbutazone, is unknown. This work reports a significant enhancement for both the extent and rate of drug release for all three forms of Syloid® silica at a 1:1 drug:silica ratio over a period of 30 min. An explanation for this increase was determined to be conversion to the amorphous form and an enhanced drug loading ability within the pores. Differences between the release profiles of the three silicas were concluded to be a consequence of the physicochemical differences between the three forms. Overall, this study confirms that Syloid® silica based excipients can be used to enhance dissolution, and potentially therefore bioavailability, for compounds with poor aqueous solubility such as phenylbutazone. In addition, it has been confirmed that drug release can be carefully tailored based on the choice of Syloid® silica and desired release profile.

AB - Three mesoporous silica excipients (Syloid® silicas AL-1 FP, XDP 3050 and XDP 3150) were formulated with a model drug known for its poor aqueous solubility, namely phenylbutazone, in an attempt to enhance the extent and rate of drug dissolution. Although other forms of mesoporous silica have been investigated in previous studies, the effect of inclusion with these specific Syloid® silica based excipients and more interestingly, with phenylbutazone, is unknown. This work reports a significant enhancement for both the extent and rate of drug release for all three forms of Syloid® silica at a 1:1 drug:silica ratio over a period of 30 min. An explanation for this increase was determined to be conversion to the amorphous form and an enhanced drug loading ability within the pores. Differences between the release profiles of the three silicas were concluded to be a consequence of the physicochemical differences between the three forms. Overall, this study confirms that Syloid® silica based excipients can be used to enhance dissolution, and potentially therefore bioavailability, for compounds with poor aqueous solubility such as phenylbutazone. In addition, it has been confirmed that drug release can be carefully tailored based on the choice of Syloid® silica and desired release profile.

KW - dissolution

KW - drug-loading

KW - phenylbutazone

KW - solubility

KW - Syloid®

KW - Syloid® silicas

KW - Solubility

KW - Phenylbutazone

KW - Drug-loading

KW - Dissolution

UR - http://www.scopus.com/inward/record.url?scp=85047262637&partnerID=8YFLogxK

U2 - 10.1016/j.jpha.2018.01.004

DO - 10.1016/j.jpha.2018.01.004

M3 - Article

VL - 8

SP - 181

EP - 186

JO - Journal of Pharmaceutical Analysis

T2 - Journal of Pharmaceutical Analysis

JF - Journal of Pharmaceutical Analysis

SN - 2095-1779

IS - 3

ER -